Italia markets closed

Immunocore Holdings plc (IMCR)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
60,23+0,77 (+1,29%)
Alla chiusura: 04:00PM EDT
60,68 +0,45 (+0,75%)
Dopo ore: 06:23PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente59,46
Aperto59,50
Denaro60,12 x 200
Lettera60,29 x 200
Min-Max giorno59,33 - 62,24
Intervallo di 52 settimane42,21 - 76,98
Volume371.808
Media Volume408.638
Capitalizzazione3,012B
Beta (5 anni mensile)0,89
Rapporto PE (ttm)N/D
EPS (ttm)-1,42
Prossima data utili08 mag 2024 - 12 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A85,31
  • GlobeNewswire

    Immunocore announces upcoming presentation and posters at ESMO 2023

    Immunocore announces upcoming presentation and posters at ESMO 2023 Long-term survival data for KIMMTRAK in previously untreated patients with metastatic uveal melanoma to be presented as a late-breaking abstract in a mini oral session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 07 October 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed

  • GlobeNewswire

    Immunocore to present at upcoming investor conferences

    Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 September 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced that management will present at the following investor co

  • GlobeNewswire

    Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update

    Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria, Finland, and Israel with additional European launches expected by year-end New Phase 3 Trial for IMC-F106C (PRAME-A02) in first-line cutaneous melanoma (PRISM-MEL301); expect first patient randomized by 1Q 2024 Enrolling patients in monotherapy and combination arms of IMC-F106C in Phase 1/2 trial, including expans